Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Coprimary end points at week 24 were change from baseline in dysphagia days, measured by a validated patient-reported modified Daily Symptom Diary, and histologic response (peak esophageal eosinophil count 6 per high-power field)
At 52 weeks, semaglutide-treated patients saw a mean improvement of 16.6 points in their scores on the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated measure of heart failure-related symptoms and physical limitations, compared with an 8.7-point improvement in the placebo group
However, those with a BMI of 27 or higher may also be eligible if they have related medical conditions like type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnea
If patients do not tolerate a dose during dose escalation, consider delaying dose escalation
Focus on Hydration
PMCID: PMC4021346
US$ 22.73
US$ 28.86
US$ 27.46
US$ 25.89
